Do India’s compulsory licences violate TRIPs?
The compulsory licence issued to Natco over Bayer’s Nexavar drug in India and Novartis’s case at the Supreme Court could set a precedent for developing countries’ approach to pharma patents. Peter Roderick and Pravin Anand take contrasting positions on the cases
Peter RoderickQueen Mary UniversityLondon...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.